Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neuroblastoma 1Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 3pembrolizumab 2Radiotherapy 2Radiation 2Gemcitabine 2Etoposide 2Doxorubicin 2Cryotherapy 2Cryosurgery 2tocilizumab 1selinexor 1robatumumab 1poly ICLC 1olaparib 1montanide ISA 51 1lentiviral minigene vaccine of COVID-19 coronavirus 1flt3 ligand protein 1eltrombopag 1cc-486 1Vincristine 1Trabectedin 1Temozolomide 1Radiotherapy, Intensity-Modulated 1Leukapheresis 1Irinotecan 1Interleukin-2 1Injections 1Imiquimod 1Ifosfamide 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Bone Neoplasms × robatumumab × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡